Swedish healthcare group Sobi has appointed Torbjorn Hallberg as its new general counsel and establishes a new leadership structure.
Hallberg, who joins from Takeda, where he served for seven years, first as senior director and corporate counsel and then more recently as its vice president, general counsel for emerging markets.
He arrives at Sobi will more than 15 years’ experience covering licensing, mergers and acquisitions at pharma groups such as Ferring and Nycomed.
Meanwhile, Sobi has also established a new leadership structure, consisting of chief executive officer Guido Oelkers, chief financial officer Mats-Olof Wallin, general counsel and head of legal affairs Carin Dahlquist (an acting role), head of EMENA Hege Hellström and head of North America Rami Levin.
Also sitting on the new team are Sobi’s head of specialty care Norbert Oppitz, head of medical and scientific affairs Armin Reininger, head of haemophilia Philip Wood and head of research and development and chief medical officer Milan Zdravkovic.
Source: PMLive
GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted antibody-drug conjugate (ADC), GSK’227, to treat adults with relapsed or refractory osteosarcoma who have progressed on a minimum of two previous lines of therapy.
As part of its long-term plans in the country, US drugmaker Merck & Co., operating as MSD outside of North America, has acquired WuXi Biologics’ site in Dundalk, Ireland, for about $500 million. The deal was announced through Ireland’s Foreign Direct Investment Agency (IDA) and MSD’s Ireland unit.
Galapagos, a biotechnology company headquartered in Belgium, plans to split into two entities: a newly formed company (name to be announced at a later date) that will focus on building a pipeline of innovative drugs through transformative transactions, and Galapagos, which will continue to develop its cell therapy manufacturing platform in oncology.
